Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
Open Access
- 1 May 2020
- journal article
- review article
- Published by Elsevier BV in Acta Pharmaceutica Sinica. B
- Vol. 10 (5), 723-733
- https://doi.org/10.1016/j.apsb.2019.09.006
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81625024)
- National Natural Science Foundation of China (81773754)
This publication has 106 references indexed in Scilit:
- The cancer-testis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivoMolecular Medicine Reports, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerThe New England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Chemotherapy Induces Intratumoral Expression of Chemokines in Cutaneous Melanoma, Favoring T-cell Infiltration and Tumor ControlCancer Research, 2011
- Quantitative expression and immunogenicity of MAGE‐3 and ‐6 in upper aerodigestive tract cancerInternational Journal of Cancer, 2009
- Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell RecruitmentCancer Research, 2009
- Interaction of human PD-L1 and B7-1Molecular Immunology, 2008
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- Functional Up-regulation of Human Leukocyte Antigen Class I Antigens Expression by 5-aza-2′-deoxycytidine in Cutaneous Melanoma: Immunotherapeutic ImplicationsClinical Cancer Research, 2007
- Epigenetic therapy of cancer: past, present and futureNature Reviews Drug Discovery, 2006